Share with the GIVE18 Community

Your donations and support are crucial to the fight against Cancer. However, if Cancer has touched your life or the life of a friend or family member you understand how important it is to know you're not alone.

To that end visit this section to:

  • read stories from survivors
  • share your gratitude, love or encouragement with the community
  • let others know that you are a GIVE18 supporter
  • challenge your golf friends to join the fight and GIVE18
  • One of the most exciting features we are implementing in the next phase of our website redesign is an interactive news and blog system. We hope to make it very easy for you to share news, personal stories, photos and encouragement.

    Continue to visit this page for progress reports on the new feature, however, in the meantime we encourage you to share your news, stories and pictures with us by clicking here to submit it via email.

    Follow one person's battle with Cancer at Grace vs Cancer - click here

    GIVE18 funded Research Sends 83-Year-Old Man Into Remission

    Burden "Brent" Brunthall, 83, of Seattle, Wash., learned he had stage 4 cancer of the carotid gland in 2010. After surgery to remove his salivary gland, followed by an aggressive radiation therapy regimen, doctors believed his cancer was in remission. Unfortunately, it showed up in his lymph nodes nine months later.

    Brunthall knew from his original workup that his tumor was human epidermal growth factor receptor-2 (HER-2) positive. With the help of his daughter - a gastrointestinal oncologist in the Seattle area - he immediately began searching for clinical trials and found an experimental HER-2 vaccine study led by Pravin Kaumaya, PhD, at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James).

    Brunthall made the cross-country flight to the OSUCCC - James to determine his eligibility for the trial and received his first vaccination in June 2012. Since that time, his only cancer treatment has been the experimental vaccine. At the end of his fourth visit to Columbus in December 2013, his OSUCCC - James oncologist, Tanios Bekaii-Saab, MD, informed him he was in remission.

    "When Dr. Saab told me my cancer cells had shrunk and I was in remission, to say the news was well beyond my expectations is an understatement," Brunthall said. "Being part of this trial has given me hope - especially for others who will face cancer in the future. If my involvement in research can help others avoid some pretty horrible chemotherapy, I've done my part."

    Brent travels back to Columbus every six months for diagnostic testing and to receive his experimental vaccine. He's happy to report that he's experienced no noticeable side effects of treatment and he isn't under any restrictions that impact his quality of life.

    "A lot of times cancer hits people in the prime of their life. But if an old guy, 83 years old, can go into remission with a vaccine," Brunthall says, "I think that is a pretty exciting statement about the strength of this research."

    The HER-2 vaccine study at the OSUCCC - James, funded in part by GIVE18 Fore Cancer Research, targets two cell-surface receptors that help sustain many types of cancer and two specific regions of the human epidermal growth factor receptor 2 (HER-2), a molecule that occurs at abnormally high levels in up to 30 percent of breast cancers.

    Please support cancer research like this study at the OSUCCC - James, You may save someone's life!